Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
Stemtech Corp (OTC:STEK), a micro-cap company with a market value of $4.3 million and impressive gross profit margins of 75%, saw Director Benjamin Nathaniel Kaplan report selling 1,000,000 shares of common stock on June 23, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The stock has declined over 34% in the past six months, according to InvestingPro data. The shares were sold at a price of $0.03, for a total transaction value of $30,000.
Following the transaction, Kaplan directly owns 831,004 shares of Stemtech Corp. Kaplan also indirectly owns 1,198,905 shares through B/O Longside Ventures LLC and 104,185 shares through B/O Triple Crown Consulting Inc.
In other recent news, Stemtech Corp announced a significant change in its financial leadership. The company revealed that James Cardwell has resigned from his position as Chief Financial Officer, effective April 11, 2025. Shrilakshmi Vadlapatla has been appointed as the new CFO, bringing extensive experience in audit compliance, SEC reporting, and strategic financial management. Her background includes expertise in risk assessment and the development of financial policies and procedures, supported by her knowledge of GAAP and IFRS. Stemtech’s CEO, Charles Arnold, officially confirmed the executive changes in an SEC filing dated April 14, 2025. The transition appears to be smooth, with no reported disagreements between Cardwell and the management. Vadlapatla’s appointment is anticipated to enhance the company’s financial compliance and reporting capabilities. This leadership change reflects Stemtech’s commitment to maintaining strong financial management and oversight.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.